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Background: An accumulating body of evidence points to the significance of neuroinflammation and immunogenetics
in schizophrenia, and an imbalance of cytokines in the central nervous system (CNS) has been suggested to be associated
with the disorder. Munc18-overexpressing mice (Munc18-OE) have provided a model for the study of the alterations
that may underlie the symptoms of subjects with schizophrenia. The aim of the present study was to elucidate the
involvement of neuroinflammation and cytokine imbalance in this model.
Methods: Cytokines were evaluated in the cortex and the striatum of Munc18-OE and wild-type (WT) mice by
enzyme-linked immunosorbent assay (ELISA). Protein levels of specific microglia and macrophage, astrocytic and
neuroinflammation markers were quantified by western blot in the cortex and the striatum of Munc18-OE and
WT mice.
Results: Each cytokine evaluated (Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-2
(IL-2) and CCL2 chemokine) was present at higher levels in the striatum of Munc18-OE mice than WT. Cortical
TNF-α and IL-2 levels were significantly lower in Munc18-OE mice than WT mice. The microglia and macrophage
marker CD11b was lower in the cortexes of Munc18-OE mice than WT, but no differences were observed in the
striatum. Glial Fibrillary Acidic Protein (GFAP) and Nuclear Factor-kappaB (NF-κB)p65 levels were not different
between the groups. Interleukin-1beta (IL-1β) and IL-6 levels were beneath detection limits.
Conclusions: The disrupted levels of cytokines detected in the brain of Munc18-OE mice was found to be similar
to clinical reports and endorses study of this type for analysis of this aspect of the disorder. The lower CD11b
expression in the cortex but not in the striatum of the Munc18-OE mice may reflect differences in physiological
activity. The cytokine expression pattern observed in Munc18-OE mice is similar to a previously published model
of schizophrenia caused by maternal immune activation. Together, these data suggest a possible role for an
immune imbalance in this disorder.
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Inflammation is a complex response of the host to tissue
injury such as an infection or a physical insult [1]. Cyto-
kines are a family of proteins that mediate host response
to infection, and are considered to be markers of infec-
tious and inflammatory conditions [2,3]. Cytokines further* Correspondence: itziar.gil@ehu.es
1Department of Neurology, Columbia University Medical Center, 710 W,
168th Street, New York, NY 10032, USA
2Department of Pharmacology, University of the Basque Country (UPV/EHU),
Barrio Sarriena s/n, Leioa, Bizkaia 48940, Spain
Full list of author information is available at the end of the article
© 2014 Gil-Pisa et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.mediate the cross-talk between the central nervous system
(CNS) and the immune system, with consequences rele-
vant to clinical psychiatry [4]. Over a decade ago, the CNS
was formerly regarded to be effectively isolated from the
peripheral immune system by the blood-brain barrier
(BBB), but presently there is no doubt that cytokines from
the peripheral immune system can invade the CNS under
particular physiological and pathological conditions [5],
and that multiple cytokines are synthesized by resident
cells of the CNS including microglia, astrocytes and neu-
rons [6-11].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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affects about 1% of the world population [12], has re-
cently been associated with increased levels of cytokines
in the CNS [13-17]. An animal model of schizophrenia
that features such aberrant cytokine handling would pro-
vide a tool for elucidating roles in the pathogenesis of
this disease and exploring novel avenues of treatment
based on immunomodulation.
Neurotransmitter release occurs mainly by exocytosis
of secretory vesicles. It has been previously shown that
cytosolic Sec/Munc (SM) proteins are involved in the
assembly of the soluble NSF-attachment protein recep-
tor (SNARE) complex and in the membranes attach-
ment [18]. We have elected to study abnormalities of
the Munc18-1 SM protein that have been implicated in
the pathogenesis of schizophrenia [19,20]. Munc18-1
participates in SNARE interactions and plays an im-
portant role in the steps leading to synaptic vesicle exo-
cytosis [21,22]. Postmortem proteomic analysis of the
prefrontal cortex of subjects with schizophrenia de-
monstrates abnormally high Munc18-1 protein levels in
membrane microdomains of the gray matter [23]. In
addition, antipsychotic drug treatment seems to be as-
sociated with a lower content of key proteins of the exocyt-
otic machinery, which could result in the destabilization
and/or impairment of neuroexocytosis [24]. Alternative
splicing of the gene coding for Munc18-1 results in two
variants, the long isoform Munc18-1a (brain and retina)
and the ubiquitous short isoform Munc18-1b [25,26].
Based on these premises, a transgenic mouse overex-
pressing the brain-specific isoform protein Munc18-1a
(Munc18-OE mouse) was developed to assess whether
abnormalities in exocytosis machinery could lead to a
schizophrenic phenotype [27]. Urigüen et al. demon-
strated that the overexpression of Munc18-1a produces
a spectrum of alterations that resemble schizophrenic
symptoms and/or neurobiological findings observed
in subjects with schizophrenia [27], including a deficit
in prepulse inhibition (PPI) and social functioning
[28,29]. Moreover, Munc18-OE animals displayed dopa-
minergic dysfunction [27], which has been proposed
as a crucial component of the pathogenesis of schizo-
phrenia [30].
The objective of the present study is to determine if
there are signs of neuroinflammation in the Munc18-
OE mouse model. A range of cytokines previously de-
scribed to be disrupted in the blood or cerebrospinal
fluid (CSF) of patients with schizophrenia [14-17] were
measured in the cortex and the striatum of Munc18-
OE mice and corresponding WT controls. We further
determined levels of specific microglia and macrophage
and astrocytic markers and NF-κB (p65), a multifunc-
tional transcription factor that is an important mediator
of inflammation [31].Methods
Animals
Assays were performed on adult (between 8 and 16-
weeks-old) male C57BL6/CBA mice (National Institute
for Agronomic Research, Madrid, Spain). Munc18-OE
mice were generated as previously described by pro-
nuclear microinjection [27]. WT mice (National Institute
for Agronomic Research, Madrid, Spain) used as con-
trols displayed the same background. A total of n = 5
animals per group and experiment were used. All ani-
mals were housed under a controlled temperature (22 ±
1°C), at a 12 hour light/dark cycle (lights on: 7:30 a.m. to
7:30 p.m.), and humidity (between 65 and 70%) with
food and water ad libitum. Mice were killed by cervical
dislocation and their brains were quickly frozen at −80°C.
The day of the experiment, the whole cerebral cortex and
the dorsal striatum of each mouse were dissected at 4°C.
All animal procedures were performed in accordance with
the European Directive for the Protection of Vertebrate
Animals used for Experimental and Other Scientific
Purposes (European Union Directive #86/606/EEC) and
approved by the UPV/EHU Ethical Board for Animal
Welfare (CEBA) and Genetically Modified Organisms
(CEIAB). More recently, new regulations for research
procedures with animals have been established (Royal
Decree 53/2013).
Enzyme-linked immunosorbent assay (ELISA)
Samples were homogenized on ice using a Sonic Dismem-
brator 60 (Thermo Fisher Scientific Inc., Massachusetts,
United States) in a cytokine extraction buffer containing
0.05% bovine serum albumin (BSA), 0.02 mg/ml aproti-
nin, 0.02 mg/ml phenylmethanesulfonyl fluoride (PMSF),
0.05 mg/ml benzethonium chloride, 0.5% polyoxyethylene
20 sorbitan monooleate or Tween 20 (purchased from
Sigma Aldrich©, Missouri, United States), 0.37 mg/ml
ethylenediaminetetraacetic acid (EDTA) and 0.023 mg/ml
sodium chloride (NaCl) (purchased from Merck, Darmstadt,
Germany) followed by centrifugation at 10,000 rpm for
10 minutes at 4°C. The cytokine levels were assessed in
the supernatants by ELISA, according to the manufac-
turer’s instructions (eBioscience Inc., California, United
States). All samples were assayed at a dilution 1:2 in the
buffer and the assays sensitivities were respectively: 0.7
to 100 pg/ml IFN-γ, 8 to 1,000 pg/ml TNF-α, 8 to 1,000
pg/ml IL-1β, 2 to 200 pg/ml IL-2, 4 to 500 pg/ml IL-6
and 15 to 2,000 pg/ml CCL2 chemokine. The Beckman
Coulter DTX 880 Multimode detector (Beckman Coulter
Inc., Califronia, United States) was used to determine the
concentration of cytokines. Sample cytokine levels were
determined using standard concentration curves evaluated
in duplicate for each plate. Data were normalized to
sample protein concentration, as determined by the
Pierce BCA Protein Assay Kit (Thermo Scientific Inc.,
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in pg cytokine/mg protein.
Immunoblot assays
Samples were homogenized on ice using a Sonic Dis-
membrator 60 in a lysis buffer containing 50 mM Tris-
HCl buffer (pH = 7.4) (Sigma Aldrich©, Missouri, United
States), 150 mM NaCl, 5 mM EDTA and 1% Triton
(Sigma Aldrich©, Missouri, United States). The protein
concentration was determined with Pierce BCA Protein
Assay Kit, using BSA as a standard. Samples were di-
luted in a loading buffer containing 70 mM Tris-HCl
(pH = 6.8), 2% sodium dodecyl sulfate (SDS), 120 mM
dithiothreitol, 6% glycerol and 0.0025% bromophenol
blue (purchased from Sigma Aldrich©, Missouri, United
States). Samples were denatured at 95°C for 5 minutes
and 20 μg of total protein were loaded on each well. Pro-
teins were separated by electrophoresis in SDS polyacryl-
amide gels and transferred to polyvinylidene fluoride
membranes. Membranes were blocked for 1 hour at
room temperature with Tris-HCl-buffered saline solu-
tion containing 5% nonfat dried milk (Sigma Aldrich©,
Missouri, United States) and 0.05% Tween 20. Mem-
branes were then incubated at 4°C overnight with spe-
cific primary antibodies: rabbit monoclonal antibody
anti-CD11b (NB110-89474, Novus Biologicals, Colorado
United States) at a dilution of 1:1,000, rabbit polyclonal
antibody anti-glial fibrillary acidic protein (GFAP) (ab7260-
50, lot No. 740637, Abcam®, Cambridge, England) at a
dilution of 1:50,000, and rabbit polyclonal antibody
anti-NF-κB (NB100-78423, lot No. B128550, Novus
Biologicals, Colorado, United States) at a dilution of 1:500.
As a control for sample loading and protein transfer, the
blots were stripped and re-probed with monoclonal anti-
body anti-β-actin (A5441, lot No. 061 M4808, Sigma
Aldrich©, Missouri, United States) at a dilution of
1:20,000. The membranes were incubated with appropri-
ate horseradish peroxidase (HRP)-conjugated secondary
antibodies (Thermo Scientific, Massachusetts, Unites
States) at a dilution of 1:20,000 in blocking solution for 1
hour at room temperature and developed with the chemi-
luminescence kit Immobilon™ Western HRP Sustrate
(Millipore, Massachusetts, United States). Target proteins
were quantified by densitometric scanning of specific im-
munoreactive bands (integrated optical density (IOD)
units). The immunoreactivity value of the target proteins
in each sample was first corrected with the corresponding
value of β-actin and then calculated as a percentage of the
corresponding mean value of the WT group, which was
used as a reference value (100%).
Data analysis
Data were analyzed with GraphPad Prism™ version 5.0
(GraphPad Software, California, United States) andInVivoStat (InVivoStat Statistical Software, United Kingdom).
Results were expressed as mean ± SEM. Data were ana-
lyzed by Student’s t-test. All tests were two-tailed. The
level of significance was set to P <0.05.
Results
Brain cytokine levels
In the brain cortex samples there were no differences
between groups in the levels of IFN-γ (Figure 1a) or
CCL2 (Figure 1b). However, cortical TNF-α (Figure 1c)
and IL-2 levels (Figure 1d) were significantly lower in
Munc18-OE mice than WT (t = 4.03, P <0.01; t = 3.62,
P <0.01, respectively).
Interestingly, all the evaluated cytokines were signifi-
cantly increased in the striatum of Munc18-OE mice com-
pared to WT mice (Figure 2): IFN-γ (t = 2.91, P <0.05),
CCL2 (t = 8.24, P <0.0001), TNF-α (t = 2.52, P <0.05), IL-
2 (t = 8.51, P <0.0001).
The levels of IL-1β and IL-6 were under detection
limits (8 pg/ml and 4 pg/ml, respectively) in both the
cortex and striatum of Munc18-OE and WT mice (data
not shown).
Brain inflammatory markers
The microglia and macrophage marker CD11b was iden-
tified by western blot as a single band of 160 kDa, GFAP
as a band of 55 kDa and the NF-κB p65 subunit as a
band of 65 kDa.
In the cortical samples, we observed lower CD11b ex-
pression (Figure 3a) in Munc18-OE mice than WT mice
(t = 3.01, P <0.05), whereas no differences were detected
in the levels of GFAP between both groups (Figure 3b).
Although no statistically significant changes were ob-
tained in the NF-κB transcription factor p65 subunit be-
tween both groups of mice, a trend of lower levels in
Munc18-OE mice was observed (Figure 3c).
None of these inflammatory parameters protein levels
differed in the striatum of Munc18-OE from those quan-
tified in WT mice (Figure 4).
Discussion
Schizophrenia is a syndrome with multiple etiologies and
symptoms, and development of relevant animal models
has relied on focusing on specific features associated with
schizophrenia, rather than mimicking the entire syn-
drome. As previously described [27], the overexpression
of Munc18-1a in mice resulted in a successful replication
of several behavioral, neurochemical and morphological
features associated with schizophrenia. Here we show that
in addition to this, the Munc18-OE mice exhibit a neu-
roinflammatory pattern that is similar to the one reported
in the genuine disease.
Interestingly, we found that IL-2 and TNF-α cortical
levels are lower in transgenic compared to WT mice,
Figure 1 Concentration of (a) IFN-γ, (b) CCL2, (c) TNF-α and (d) IL-2 in cortical homogenate from Munc18-OE (n = 5) and wild-type
(n = 5) mice. IFN-γ and CCL2 cortical levels were not different between groups. However, Munc18-OE mice showed a significant decrease in TNF-α
and IL-2 cortical concentrations (t = 4.03, P <0.01; t = 3.62, P <0.01, respectively) compared to the WT. Data are expressed in pg cytokine/mg protein.
Figure 2 Concentration of (a) IFN-γ, (b) CCL2, (c) TNF-α and (d) IL-2 in striatal homogenate from Munc18-OE (n = 5) and wild-type
(n = 5) mice. All cytokines were significantly increased in the striatum of Munc18-OE mice compared to WT mice showing significant differences
between groups: IFN-γ (t = 2.91, P <0.05), CCL2 (t = 8.24, P <0.0001), TNF-α (t = 2.52, P <0.05), IL-2 (t = 8.51, P <0.0001). Data are expressed in pg
cytokine/mg protein.
Gil-Pisa et al. Journal of Neuroinflammation 2014, 11:128 Page 4 of 8
http://www.jneuroinflammation.com/content/11/1/128
Figure 3 Immunodensities of (a) CD11b, (b) GFAP and (c) NF-κB (p65) proteins with representative immunoblots in cerebral cortex
from Munc18-OE (n = 5) and wild-type (n = 5) mice. Bar graphs are ratios of optical densities of our proteins of interest to β-actin (42 kDa
band), expressed as immunoreactivity in percentage of the mean value of the WT group (100%). CD11b was significantly decreased in Munc18-OE
mice compared to the WT (t = 3.01; P <0.05). No differences between groups were observed in the levels of GFAP or NF-κB. Right panels are
representative immunoblots for target proteins and β-actin which included Munc18-OE (OE) and wild-type (WT) mice samples. The molecular
masses were estimated from referenced standards.
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http://www.jneuroinflammation.com/content/11/1/128and that the levels of microglia and macrophage marker
CD11b are also decreased in the cortex of Munc18-OE
mice. The decreased TNF-α in the cortex of Munc18-OE
mice could be responsible for reduced microglia activation
displayed by decreased microglia and macrophage marker
CD11b expression. Furthermore, IL-2 cytokine, which was
also decreased in the cortex, is mostly synthesized by
activated microglia in the CNS [32]. In contrast, a non-
statistically significant trend to reduced NF-κB was ob-
served, mainly in the cortex. Taking into account the
sample size, a type II error cannot be discarded for the
differences between groups obtained in the cortex and
the striatum for NF-κB. Thus, the non-significant de-
crease displayed by the Munc18-OE animal model
might be relevant to schizophrenia, a disease associatedwith increased NF-κB levels in peripheral tissues of
schizophrenic subjects. However, these alterations in the
cytokine network in schizophrenia might be secondary to
antipsychotic treatment, which has an important impact
on the immune system [33,34]. Indeed, the status of NF-
κB in drug-free schizophrenic subjects remains to be elu-
cidated. Globally, the present results could be suggesting a
decrease in proinflammatory pathways in the cerebral cor-
tex of Munc18-OE mice compared to WT mice.
It is remarkable that the levels of proinflammatory cyto-
kines are decreased in the cortex of transgenic mice com-
pared to WT, whereas these levels are increased in the
striatum. This would be consistent with previous data that
indicate opposite or compensatory effects to the cortex
and striatum of schizophrenic patients [35,36].
Figure 4 Immunodensities of (a) CD11b, (b) GFAP and (c) NF-κB (p65) proteins with representative immunoblots in striatum from
Munc18-OE (n = 5) and wild-type (n = 5) mice. Bar graphs are ratios of optical densities of our proteins of interest to β-actin (42 kDa band),
expressed as immunoreactivity in percentage of mean value of the WT group (100%). No differences were detected between groups for any of
the analyzed proteins. Right panels are representative immunoblots for target proteins and β-actin which included Munc18-OE (OE) and wild-type
(WT) mice samples. The molecular masses were estimated from referenced standards.
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of the symptoms of schizophrenia could be ascribed to
the disruption of the prefrontal cortex (hypofrontality)
[37-39]. This phenomenon could involve not only hypo-
functional areas but areas of overactivity as well, such as
temporal or limbic areas [37]. Furthermore, it has been
suggested that the cortical state underlies the negative
symptoms and cognitive impairments in schizophrenia,
contributing to the typical poor social outcome of this
disease, while the subcortical state underlies the positive
symptoms. Additionally, there are findings consistent
with the notion that impaired prefrontal dopamine (DA)
transmission may be related to hypofrontality [40]. Fur-
thermore, this hypodopaminergic state in the cortex may
produce a subsequent hyperdopaminergic state in thesubcortical regions [35,41,42], due to the fact that cor-
tical pathways exert an inhibitory control of subcortical
DA transmission [43,44]. Functional imaging studies in
schizophrenic patients have shown reduced frontal lobe
activity, that is, reduced glucose utilization and decreased
regional cerebral blood flow [38,45-47]. Decreased levels
of proinflammatory cytokines in the cortex, followed by
an increase of these cytokines in the striatum, could be a
compensatory mechanism similar to the compensatory
hyperactivity observed in schizophrenic patients.
Additionally, immune and inflammatory processes in
prenatal and perinatal stages are suggested to play cru-
cial roles in the vulnerability to schizophrenia. Munc18-
OE mice show symptoms similar to those induced in
adult offspring by the polyinosinic:polycytidylic acid
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phrenia [48-50]. It would be interesting to evaluate neu-
roinflammation in other animal models to elucidate
whether this potential correlation between a disruption
in the levels of proinflammatory markers and schizo-
phrenia is present.
As above, CNS measured cytokines may originate na-
tive or infiltrated cells in the CNS or peripheral cyto-
kines could be transported across the BBB [51,52].
While we find that the brain of Munc18-OE mice
presents an imbalance of immune and inflammatory
systems, further studies including activity experiments
should be carried out to identify the sources of the
altered inflammatory signals observed in transgenic
mice.
In summary, the overexpression of Munc18-1a results
in an imbalance of immune and inflammatory systems,
which may be induced directly or indirectly. Multiple
secretory pathways for cytokines have been characterized,
including regulated exocytosis which involves SNARE and
SM proteins [53]. Furthermore, Munc18-OE mice dis-
played dopaminergic dysfunction, consistent with reports
that neurotransmitters may modulate microglia-mediated
neuroinflammation [54]. Nevertheless, further studies
are necessary to elucidate the mechanism leading from
Munc18-1a overexpression to the disrupted immune
and inflammatory systems.
We note that immunological and inflammatory pa-
rameters related to schizophrenia have been determined
mainly in peripheral human samples such as blood and
CSF [14-17], and there is a dearth of data in levels of
proinflammatory markers in human brain tissue, which
will be required to provide insight into the relevance of
these models.Conclusions
The cytokine levels measured in the brains of Munc18-
OE mice are consistent with data obtained in patients
with schizophrenia that indicate hypofrontality and stria-
tal overactivity. The Munc18-OE mice displayed similar
symptoms to those induced by maternal immune activa-
tion, suggesting a potential convergence of immune im-
balance in the schizophrenic phenotype derived from
multiple etiologies. It is noteworthy that these findings
are consistent with the growing evidence that immunity
and inflammatory imbalance seems to be related to the
pathophysiology of schizophrenia [55].
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